Hot on the heels of gaining US Food and Drug Administration approval for its lead candidate Fotivda (tivozanib), US biotech AVEO Oncology (Nasdaq: AVEO) says it has entered into a clinical trial collaboration and supply agreement with US pharma major Bristol Myers Squibb (NYSE: BMY).
The aim is to evaluate Fotivda in combination with BMS’ blockbuster anti-PD-1 therapy Opdivo (nivolumab), in the pivotal Phase III TiNivo-2 trial in patients with relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
The news was welcomed, as the FDA approval of Fotivda was based on a clinical trial comparing it with what was viewed an obsolete drug, at best showing no overall survival advantage, and pushed AVEO’s shares up 6.6% to $12.65 in morning trading today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze